NEW YORK – Greenwich LifeSciences said on Thursday that Baylor College of Medicine will serve as the lead site for a Phase III study evaluating its investigational immunotherapy, called GP2, for the prevention of breast cancer recurrence.
The Stafford, Texas-based drug developer is still working out the protocol of the study, in which researchers hope to explore the ability of GP2 to prevent recurrence in HER2-postive breast cancer patients who have undergone surgery.